The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma

BACKGROUND: Advanced gastric cancer (GC) is a lethal malignancy, harboring recurrent alterations in cell cycle pathway, especially the CDKN2A-CDK4/CDK6/CCND1 axis. However, monotherapy of CDK4/6 inhibitors has shown limited antitumor effects for GC, and combination treatments were urgently needed fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Mei, Xu, Hao, Zhou, Wenyuan, Pan, Yisheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909925/
https://www.ncbi.nlm.nih.gov/pubmed/36755269
http://dx.doi.org/10.1186/s13046-023-02615-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909925/
https://www.ncbi.nlm.nih.gov/pubmed/36755269
http://dx.doi.org/10.1186/s13046-023-02615-2

Ejemplares similares